Tumor Biology

, Volume 37, Issue 1, pp 619–625 | Cite as

Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes

  • Dong Soo Lee
  • Kyung Ran Park
  • Seung Joon Kim
  • Mi Joo Chung
  • Yun Hee Lee
  • Ji Hyun Chang
  • Jin Hyoung Kang
  • Sook Hee Hong
  • Myung Sin Kim
  • Yeon Sil Kim
Original Article


This study aimed to evaluate the clinical correlations between serum lactate dehydrogenase (LDH) levels and tumor characteristics and to investigate the prognostic impact of serum LDH levels in advanced non-small cell lung cancer (NSCLC). A total of 394 patients were included in the present study between June 2007 and January 2013. All eligible patients had serum LDH levels available before treatment, and whole-body metastatic extent was measured using whole-body metastatic scores, as determined by 18(F)-fludeoxyglucose positron emission tomography scans from 1 to 7 as the sum of each metastatic region. The diagnostic cutoff value for an abnormal serum LDH level was 450 IU/L. The median serum LDH level was 477 IU/L (range, 113–2850), and 224 (56.9 %) patients had abnormal serum LDH levels. The serum LDH levels showed no significant associations with age, gender, histology, tumor differentiation, and smoking history. However, the proportion of patients with abnormal serum LDH levels was statistically significantly higher in the high total metastatic score group (scores 3–7) than in the low total metastatic score group (scores 1–2) (65.3 vs 50.4 %, p = 0.001). In a multivariate survival analysis, age (p = 0.001), gender (p = 0.001), histology (p = 0.003), tumor differentiation (p = 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.001), LDH levels (p = 0.046), and treatment factors (p = 0.001) proved to be independent prognostic factors for survival outcomes. The results of this study suggest that the serum LDH levels at presentation may be significantly correlated with whole-body tumor extent and might independently but modestly prognosticate OS in stage IV NSCLC.


Lactate dehydrogenase Metastases Non-small cell lung cancer Prognosis 


Conflict of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986;4:1604–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618–26.CrossRefPubMedGoogle Scholar
  4. 4.
    Espinosa E, Feliu J, Zamora P, Gonzalez Baron M, Sanchez JJ, Ordon EZA, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 1995;12:67–76.CrossRefPubMedGoogle Scholar
  5. 5.
    Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer. 1995;13:253–67.CrossRefPubMedGoogle Scholar
  6. 6.
    Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer. 2001;85:1634–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer. 2001;34 Suppl 4:S95–101.CrossRefPubMedGoogle Scholar
  8. 8.
    Jeremic B, Milicic B, Dagovic A, Aleksandrovic J, Nikolic N. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol. 2003;129:114–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Toh CK. The changing epidemiology of lung cancer. Methods Mol Biol. 2009;472:397–411.CrossRefPubMedGoogle Scholar
  10. 10.
    Konopa K, Jassem J. The role of pemetrexed combined with targeted agents for non-small cell lung cancer. Curr Drug Targets. 2010;11:2–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Somaiah N, Simon GR. Molecular targeted agents and biologic therapies for non-small cell lung cancer. J Thorac Oncol. 2010;5:S434–54.CrossRefPubMedGoogle Scholar
  12. 12.
    Tas F, Aydiner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol. 2001;24:376–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89:877–85.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Koukourakis MI, Giatromanolaki A, Sivridis E. Tumour, Angiogenesis Research G. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol. 2003;24:199–202.CrossRefPubMedGoogle Scholar
  15. 15.
    Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012;106:799–804.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, et al. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer. 2014;14:110.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Watine J. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand J Clin Lab Invest. 2000;60:259–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang S, Han X, Hu X, Wang X, Zhao L, Tang L, et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta. 2014;430:63–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Lee DS, Kim SJ, Kang JH, Hong SH, Jeon EK, Kim YK, et al. Serum carcinoembryonic antigen levels and the risk of whole-body metastatic potential in advanced non-small cell lung cancer. J Cancer. 2014;5:663–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lee DS, Kim YS, Jung SL, Lee KY, Kang JH, Park S, et al. The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer. Tumour Biol. 2012;33:1065–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee DS, Kang JH, Lee CG, Kim SJ, Choi YJ, Lee KY, et al. Predicting survival in patients with advanced non-squamous non-small cell lung cancer: validating the extent of metastasis. Cancer Res Treat. 2013;45:95–102.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987;39:146–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys. 1986;12:771–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Ferrigno D, Buccheri G, Camilla T. Serum copper and zinc content in non-small cell lung cancer: abnormalities and clinical correlates. Monaldi Arch Chest Dis. 1999;54:204–8.PubMedGoogle Scholar
  25. 25.
    Ray P, Quantin X, Grenier J, Pujol JL. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev. 1998;22:293–304.CrossRefPubMedGoogle Scholar
  26. 26.
    Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res. 1964;24:389–99.PubMedGoogle Scholar
  27. 27.
    Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011;17:4892–900.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yang Y, Su D, Zhao L, Zhang D, Xu J, Wan J, et al. Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells. Oncotarget. 2014;5:11886–96.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol. 1997;26:14–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, et al. Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol. 2009;4:1136–43.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Dong Soo Lee
    • 1
  • Kyung Ran Park
    • 2
  • Seung Joon Kim
    • 3
  • Mi Joo Chung
    • 1
  • Yun Hee Lee
    • 1
  • Ji Hyun Chang
    • 1
  • Jin Hyoung Kang
    • 4
  • Sook Hee Hong
    • 4
  • Myung Sin Kim
    • 5
  • Yeon Sil Kim
    • 1
  1. 1.Department of Radiation Oncology, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  2. 2.Department of Radiation Oncology, School of MedicineEwha Womans UniversitySeoulSouth Korea
  3. 3.Division of Pulmonology, Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  4. 4.Department of Medical Oncology, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  5. 5.Department of Laboratory Medicine, College of MedicineThe Catholic University of KoreaSeoulSouth Korea

Personalised recommendations